Regarding molecular biomarkers, while patients with primary tumours harbouring BRAF mutation should not be considered for LT, there is no specific contraindication for RAS mutations, although these mutations are associated with a slightly worse prognosis compared with wild-type tumours. This evidence concerns the gene BRAF and neoplasm.